HGF and coronary artery disorder: The clinical application of Ad-HGF has been currently approved by the State Food and Drug Administration (SFDA) of China (No. 2005L01181); the phase I clinical study showed that it is safe and feasible to use an adenovirus gene-transfer vector to deliver the human HGF to individuals with clinically significant coronary artery diseases[10].